Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma Progressed After Immune Checkpoint Inhibitors:a Single-arm,Open-label Prospective Trial

NCT04948125 is registered in ClinicalTrials.gov with Henan Cancer Hospital as lead sponsor.

NCT NCT04948125
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04948125 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma Progressed After Immune Checkpoint Inhibitors:a Single-arm,Open-label Prospective Trial
Lead sponsor
Henan Cancer Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
April 28, 2021
Completion date
August 3, 2023
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced gastric carcinoma